Immunotherapy for hepatocellular carcinoma treatment the future is soon enough

Main Article Content

Nopavut Geratikornsupuk, M.D.
Piyawat Komolmit, M.D., Ph.D.


Immunotherapy, Immune checkpoint inhibitors, Hepatocellular carcinoma


Hepatocellular carcinoma (HCC) is a malignancy with rapidly progressive and poor prognosis. Data from the Thai national public health survey in 2016, liver cancer became the number one leading cause of death. Strategies using immunotherapy, including immune checkpoint inhibitors, have shown promising results as the second-line treatment for advanced HCC after the standard of care and targeted therapy. This review is the update on the important clinical studies, current clinical application, and future perspectives on the immunotherapy in HCC.


Abstract 76 | PDF Downloads 293